Theravance Biopharma, Inc.

NASDAQ:TBPH

Biotechnology

Healthcare
$17.03 -0.42%

-$0.07 today

Market cap
$882.64M
Beta
0.18
P/E (TTM)
7.4
EPS (TTM)
$2.23
52W Low $10.44High $21.03

Volume 10.02M

Average 0.43M

TBPH Other Non-current Assets

Long-term assets not reported separately.

Theravance Biopharma, Inc.NASDAQ: TBPH

Other Non-current Assets · Q1 FY2026 · quarter ended Mar 2026

Other non-current assets falls 84.1% from a year ago

Other non-current assets stood at $25.3M at the end of Q1 FY2026, down 84.1% from a year earlier and up 12.5% from the prior quarter. Over 3 fiscal years it compounded at -51.9% a year.

Context

  • Other non-current assets amounted to 5.4% of total assets at the end of Q1 FY2026, down 40.9 pp from a year earlier.
  • Other non-current assets increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether other non-current assets keeps falling in the next quarterly balance sheet after a -84.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$25.3M+12.5% QoQ
Last fiscal yearDec 2025
$22.5M-85.7% YoY
Year agoMar 2025
$158.86M-84.1% since
Other Non-current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-84.1%——
1 year-85.7%——
3-year CAGR-51.9%——
5-year CAGR——
10-year CAGR——

Other Non-current Assets history

USD · from the balance sheet

Latest · FY2025
22.5M USD
Year-over-year change
-85.7%
4-year CAGR
+62.5%

Other Non-current Assets vs competitors

How TBPH compares with its peers on the latest reported figures

  • Peers report in different currencies, so other non-current assets is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -84.1% is the lowest of 9, against a peer median of +18.2%.
  • Other non-current assets amounts to 5.4% of total assets for TBPH, versus a peer median of 1.2%.
TBPH Competitors
Other Non-current Assets for TBPH and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
VIRVir Biotechnology, Inc.Mar 2026$31M USD+155.5%—3.0%
TBPHTheravance Biopharma, Inc.Mar 2026$25.3M USD-84.1%-51.9%5.4%
TYRATyra Biosciences, Inc.Mar 2026$10.77M USD-5.9%+24.3%2.6%
GERNGeron CorporationMar 2026$7.9M USD+95.9%+14.5%1.5%
VALNValneva SEMar 2026€7.58M EUR-9.2%-2.9%2.0%
GLUEMonte Rosa Therapeutics, Inc.Mar 2026$5.78M USD+8.6%+3.5%0.8%
LENZLENZ Therapeutics, Inc.Mar 2026$2.45M USD+75.5%+334.4%0.9%
REPLReplimune Group, Inc.Dec 2025$1.2M USD-58.6%+21.1%0.4%
AVBPArriVent BioPharma, Inc. Common StockMar 2026$225K USD+27.8%+53.2%0.1%
Peer median (excluding TBPH) —+18.2%+21.1%1.2%

Competitors are the stored peer set for TBPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents89.96M298.17M39.55M37.8M167.81M
Short-term Investments83.51M29.31M62.88M50.55M147.55M
Net Receivables57.6M16.79M17.47M68.44M95.54M
Inventory00000
Other Current Assets8.56M7.68M11.6M4.2M7.56M
Total Current Assets249.87M353.46M133.54M161.07M418.46M
Property, Plant & Equipment (Net)53.35M52M45.36M35.77M30.27M
Goodwill00000
Intangible Assets00000
Long-term Investments68.37M00014.35M
Tax Assets00000
Other Non-current Assets3.23M201.94M203.1M157.32M22.5M
Total Non-current Assets124.95M253.94M248.46M193.09M67.11M
Total Assets374.82M607.4M382M354.16M485.57M
Account Payables3.1M1.55M1.52M2.24M2.57M
Short-term Debt17.44M00010.95M
Tax Payables0005.85M0
Deferred Revenue98K24K000
Other Current Liabilities25.15M(24K)12.88M06.91M
Total Current Liabilities58.59M28.72M24.77M32.09M38.3M
Long-term Debt599.39M00032.8M
Deferred Tax Liabilities240K00085.68M
Deferred Revenue (Non-current)310K192K000
Other Non-current Liabilities2.18M91.29M99M107.42M313K
Total Non-current Liabilities654.81M136.89M144.24M146.53M150.55M
Total Liabilities713.39M165.6M169M178.62M188.85M
Common Stock1K1K001K
Retained Earnings(1.73B)(853.91M)(909.1M)(965.52M)(859.63M)
Accumulated OCI(0)(15K)(65K)7K61K
Other Stockholders Equity00(0)(0)0
Minority Interest00000
Total Equity(338.57M)441.8M213M175.55M296.72M
Total Debt669.52M52.16M49.16M49.82M75.5M
Net Debt579.56M(246.01M)9.61M12.02M(92.31M)

Theravance Biopharma, Inc.

NASDAQ:TBPH

Intrinsic Alpha fair value

Locked

Current Price

$17.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.